Have thought for a while that they are seriously undervalued....

Have thought for a while that they are seriously undervalued. Nice suite of products, sales building, inroads into china, enlarging there chain of distributors, lowering expenses, think there are good synergies with the THOR aquisition and they have expanded manufacturing resources. Same FDA rebate as atcor but significantly cheaper product.

Chair has a lot of skin in the game.

Surely once they role out the rebranded THOR products and the BP+ product they are going to brake over into profitability and re-rating.

Negatives, seriously illiquid and has been no clearing of any overhang from the recent cr.